Friday, 16 October 2026European Markets

SALMONES CAMANCHAC And HEINEKEN HOLDING Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(VIANEWS) - SALMONES CAMANCHAC (SACAM.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Consumer Defensive sector.

Financial Asset Price Forward Dividend Yield Return on Equity
SALMONES CAMANCHAC (SACAM.OL) kr32.00 11.2% 3.92%
HEINEKEN HOLDING (HEIO.AS) €71.05 2.68% 12.83%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. SALMONES CAMANCHAC (SACAM.OL)

11.2% Forward Dividend Yield and 3.92% Return On Equity

Salmones Camanchaca S.A. engages in the salmon farming business in Chile. The company offers Atlantic and Coho salmon products in various formats, such as whole, fillet, portion, and other products including bits and pieces, harasu, and scrape meat. It also exports its products. The company was incorporated in 2009 and is based in Puerto Montt, Chile. Salmones Camanchaca S.A. is a subsidiary of Compañía Pesquera Camanchaca S.A.

Earnings Per Share

As for profitability, SALMONES CAMANCHAC has a trailing twelve months EPS of kr1.17.

PE Ratio

SALMONES CAMANCHAC has a trailing twelve months price to earnings ratio of 27.35. Meaning, the purchaser of the share is investing kr27.35 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.92%.

More news about SALMONES CAMANCHAC.

2. HEINEKEN HOLDING (HEIO.AS)

2.68% Forward Dividend Yield and 12.83% Return On Equity

Heineken Holding N.V., through its subsidiaries, engages in brewing and selling beer and cider in the Netherlands and internationally. The company's portfolio consists of approximately 300 international, regional, local, and specialty beers and ciders. The company was founded in 1864 and is based in Amsterdam, the Netherlands. Heineken Holding N.V. operates as a subsidiary of L'Arche Green N.V.

Earnings Per Share

As for profitability, HEINEKEN HOLDING has a trailing twelve months EPS of €4.5.

PE Ratio

HEINEKEN HOLDING has a trailing twelve months price to earnings ratio of 15.79. Meaning, the purchaser of the share is investing €15.79 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.83%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, HEINEKEN HOLDING's stock is considered to be oversold (<=20).

Yearly Top and Bottom Value

HEINEKEN HOLDING's stock is valued at €71.05 at 01:30 EST, way below its 52-week high of €88.85 and above its 52-week low of €69.50.

Volatility

HEINEKEN HOLDING's last week, last month's, and last quarter's current intraday variation average was a negative 0.14%, a negative 0.05%, and a positive 0.76%.

HEINEKEN HOLDING's highest amplitude of average volatility was 0.67% (last week), 0.80% (last month), and 0.76% (last quarter).

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Aug 2, 2023, the estimated forward annual dividend rate is 1.92 and the estimated forward annual dividend yield is 2.68%.

More news about HEINEKEN HOLDING.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com